175 related articles for article (PubMed ID: 35037762)
41. Axillary surgery for breast cancer: past, present, and future.
Noguchi M; Inokuchi M; Noguchi M; Morioka E; Ohno Y; Kurita T
Breast Cancer; 2021 Jan; 28(1):9-15. PubMed ID: 33165758
[TBL] [Abstract][Full Text] [Related]
42. Arm morbidity following sentinel lymph node biopsy or axillary lymph node dissection: a study from the Danish Breast Cancer Cooperative Group.
Husted Madsen A; Haugaard K; Soerensen J; Bokmand S; Friis E; Holtveg H; Peter Garne J; Horby J; Christiansen P
Breast; 2008 Apr; 17(2):138-47. PubMed ID: 17928226
[TBL] [Abstract][Full Text] [Related]
43. Axillary reverse mapping using fluorescence imaging is useful for identifying the risk group of postoperative lymphedema in breast cancer patients undergoing sentinel node biopsies.
Sakurai T; Endo M; Shimizu K; Yoshimizu N; Nakajima K; Nosaka K; Dai Y; Iwao A; Jinnai Y
J Surg Oncol; 2014 May; 109(6):612-5. PubMed ID: 24310418
[TBL] [Abstract][Full Text] [Related]
44. Altered lymphatic drainage patterns in re-operative sentinel lymph node biopsy for ipsilateral breast tumor recurrence.
Sato A; Sakai T; Iwase T; Kano F; Kimura K; Ogiya A; Koizumi M; Tanabe M; Horii R; Akiyama F; Ueno T; Ohno S
Radiat Oncol; 2019 Sep; 14(1):159. PubMed ID: 31477153
[TBL] [Abstract][Full Text] [Related]
45. The effect of immediate lymphatic reconstruction on the post-operative drain output after axillary lymph node dissection for breast cancer: A retrospective comparative study.
Lin YS; Kuan CH; Tsai LW; Wu CH; Huang CH; Yeong EK; Tai HC; Huang CS
Microsurgery; 2023 Sep; 43(6):555-562. PubMed ID: 36762663
[TBL] [Abstract][Full Text] [Related]
46. Axillary reverse mapping with indocyanine green or isosulfan blue demonstrate similar crossover rates to radiotracer identified sentinel nodes.
Foster D; Choy N; Porter C; Ahmed S; Wapnir I
J Surg Oncol; 2018 Mar; 117(3):336-340. PubMed ID: 29228459
[TBL] [Abstract][Full Text] [Related]
47. Lymphoscintigraphic and intraoperative detection of the sentinel lymph node in breast cancer patients: the nuclear medicine perspective.
Mariani G; Erba P; Villa G; Gipponi M; Manca G; Boni G; Buffoni F; Castagnola F; Paganelli G; Strauss HW
J Surg Oncol; 2004 Mar; 85(3):112-22. PubMed ID: 14991882
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of axillary reverse mapping (ARM) in clinically axillary node negative breast cancer patients - Randomised controlled trial.
Abdelhamid MI; Bari AA; Farid MI; Nour H
Int J Surg; 2020 Mar; 75():174-178. PubMed ID: 32059974
[TBL] [Abstract][Full Text] [Related]
49. Comparison of upper extremity lymphedema after sentinel lymph node biopsy and axillary lymph node dissection: patient-reported outcomes in 3044 patients.
Poulsen L; Kaur M; Jacobsen AL; Bjarnesen MP; Bjarnesen AP; Klassen AF; Pusic AL; de Vries CEE; Sørensen JA
Breast Cancer Res Treat; 2022 Jan; 191(1):87-96. PubMed ID: 34643834
[TBL] [Abstract][Full Text] [Related]
50. Radioguided sentinel lymph node biopsy in breast cancer surgery.
Mariani G; Moresco L; Viale G; Villa G; Bagnasco M; Canavese G; Buscombe J; Strauss HW; Paganelli G
J Nucl Med; 2001 Aug; 42(8):1198-215. PubMed ID: 11483681
[TBL] [Abstract][Full Text] [Related]
51. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes.
Veronesi U; Paganelli G; Galimberti V; Viale G; Zurrida S; Bedoni M; Costa A; de Cicco C; Geraghty JG; Luini A; Sacchini V; Veronesi P
Lancet; 1997 Jun; 349(9069):1864-7. PubMed ID: 9217757
[TBL] [Abstract][Full Text] [Related]
52. Initial experience with sentinel node biopsy in breast cancer at the National Cancer Center Hospital East.
Imoto S; Hasebe T
Jpn J Clin Oncol; 1999 Jan; 29(1):11-5. PubMed ID: 10073145
[TBL] [Abstract][Full Text] [Related]
53. Sentinel node biopsy versus low axillary sampling in women with clinically node negative operable breast cancer.
Parmar V; Hawaldar R; Nair NS; Shet T; Vanmali V; Desai S; Gupta S; Rangrajan V; Mittra I; Badwe RA
Breast; 2013 Dec; 22(6):1081-6. PubMed ID: 23948301
[TBL] [Abstract][Full Text] [Related]
54. Neoadjuvant Treatment as a Risk Factor for Variation of Upper Limb Lymph Node Drainage During Axillary Reverse Mapping in Breast Cancer: A Prospective Observational Study.
Vanni G; Pellicciaro M; Materazzo M; Melaiu O; Longo B; Cervelli V; Buonomo OC
Anticancer Res; 2022 Aug; 42(8):3879-3888. PubMed ID: 35896226
[TBL] [Abstract][Full Text] [Related]
55. Clinical application of axillary reverse mapping in patients with breast cancer: A systematic review and meta-analysis.
Wijaya WA; Peng J; He Y; Chen J; Cen Y
Breast; 2020 Oct; 53():189-200. PubMed ID: 32858404
[TBL] [Abstract][Full Text] [Related]
56. Patterns of lymphatic drainage after axillary node dissection impact arm lymphoedema severity: A review of animal and clinical imaging studies.
Suami H; Koelmeyer L; Mackie H; Boyages J
Surg Oncol; 2018 Dec; 27(4):743-750. PubMed ID: 30449502
[TBL] [Abstract][Full Text] [Related]
57. Lymphoscintigraphy in patients with breast cancer-related lymphedema after sentinel lymph node dissection and axillary radiation therapy.
Oh SH; Kim JH; Seong ST; Park JY; Lee JH; Kim GC; Jeong HJ; Sim YJ
Medicine (Baltimore); 2022 Dec; 101(49):e31985. PubMed ID: 36626428
[TBL] [Abstract][Full Text] [Related]
58. The Feasibility and Oncological Safety of Axillary Reverse Mapping in Patients with Breast Cancer: A Systematic Review and Meta-Analysis of Prospective Studies.
Han C; Yang B; Zuo WS; Zheng G; Yang L; Zheng MZ
PLoS One; 2016; 11(2):e0150285. PubMed ID: 26919589
[TBL] [Abstract][Full Text] [Related]
59. Comparative morbidity of axillary lymph node dissection and the sentinel lymph node technique: implications for patients with breast cancer.
Silberman AW; McVay C; Cohen JS; Altura JF; Brackert S; Sarna GP; Palmer D; Ko A; Memsic L
Ann Surg; 2004 Jul; 240(1):1-6. PubMed ID: 15213610
[TBL] [Abstract][Full Text] [Related]
60. Occurrence of breast-cancer-related lymphedema after reverse lymphatic mapping and selective axillary dissection versus standard surgical treatment of axilla: A two-arm randomized clinical trial.
Gennaro M; Maccauro M; Mariani L; Listorti C; Sigari C; De Vivo A; Chisari M; Maugeri I; Lorenzoni A; Aliberti G; Scaperrotta GP; Caraceni A; Pruneri G; Folli S
Cancer; 2022 Dec; 128(24):4185-4193. PubMed ID: 36259883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
